What Pivotal bioVenture Partners Investment Advisor LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1844645 · Filed Aug 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.3M |
| −6.7% |
| $33.2M |
| 10.8% |
TRVITrevi Therapeutics, Inc. | 1.7M | +12.2% | $32.5M | 10.6% |
AVLNAvalyn Pharma Inc. | 966.8K | New | $31.8M | 10.3% |
EVMNEvommune, Inc. | 1.9M | ±0% | $25.6M | 8.3% |
MPLTMapLight Therapeutics, Inc. | 611.4K | −0.0% | $21.9M | 7.1% |
OCSOculis Holding AG | 1.5M | −10.4% | $20.9M | 6.8% |
BIOABioAge Labs, Inc. | 653.4K | ±0% | $16M | 5.2% |
IMNMImmunome Inc. | 732.5K | ±0% | $15.5M | 5% |
ZBIOZenas BioPharma, Inc. | 490.8K | −17.1% | $12.5M | 4% |
AVTXAvalo Therapeutics, Inc. | 434K | +46.7% | $8M | 2.6% |
RLYBRallybio Corp | 300.6K | ±0% | $4.8M | 1.6% |
RXRXRecursion Pharmaceuticals, Inc. | 595.5K | ±0% | $2.2M | 0.7% |
